(Adnkronos) - Le nuove terapie basate sulla somministrazione di anticorpi monoclonali si sono rivelate efficaci nella riduzione della disabilità e nel miglioramento della qualità di vita delle persone con emicrania, con risultati in real life addirittura superiori a quelli ottenuti durante i trial clinici. Si tratta di progressi particolarmente importanti, ma è altrettanto cruciale che la patologia venga riconosciuta ufficialmente come malattia cronica all’interno del Piano nazionale sulla cronicità e che vengano definiti percorsi integrati a livello nazionale per la presa in carico precoce dei pazienti. Se ne è parlato a Roma all’evento ‘Empatia, empowerment, emicrania: vivere la vita’, organizzato da Organon Italia.
Category
🗞
NewsTranscript
00:00Hemicrania is the first cause of invalidity among young women and source of huge costs
00:08for the national health service.
00:10The intense and pulsating headache, which is often accompanied by nausea, vomiting, increase
00:15of sensitivity to light, sounds, noises, odors and fatigue, compromises the quality of life
00:20of about 6 million people in Italy, two-thirds of whom of female sex.
00:25Of the new treatment opportunities, represented above all by monoclonal antibodies,
00:30of the importance that the pathology is recognized as a chronic disease and inserted in the national plan
00:34on chronicity, and of the new guidelines defined by the international scientific community,
00:40it was discussed at the Empathia Empowerment Hemicrania event,
00:43Vivere la Vita, organized in Rome by Organon Italia.
00:47We will have a list of drugs with comments from experts that will be supported by the other guidelines.
00:54The main intention is to unify as much as possible the approach to subjects with hemicrania
01:02a little all over the world, not only in Italy, not only in different countries.
01:06We have many drugs and our idea would be to make these drugs available to all people
01:13who suffer from this disease, because it is disabling, because these drugs are effective,
01:18because especially the new ones are very well tolerated, so they do not need monitoring,
01:24they do not create toxicity, and so this was a first step.
01:27A second step we have taken is to decline the effectiveness of drugs in practical recommendations.
01:34The effectiveness, tolerance and safety of the use of monoclonal antibodies in hemicranial patients
01:39has been confirmed in clinical practice, with results higher than those recorded during the trials.
01:45The real-life evidence that has happened in recent years, that have become copious,
01:51and that represent the results of the clinical practice that we do daily in our ambulatories with our patients,
01:57has even increased the results in terms of effectiveness, quality of life, disability in patients treated with monoclonal antibodies.
02:08To deal with hemicrania, a holistic approach is therefore required,
02:12which includes care and prevention through the tempestuous use of new therapies
02:16and provides a rapid and multidisciplinary takeover of the patient.
02:20It has become important, as it has been repeated in recent years,
02:24to go and define integrated paths, even organizational models,
02:29related to the takeover and the early diagnosis of patients affected by hemicrania,
02:34because this is the only possible strategy that can help us to stratify the different types of patients,
02:40to understand which of these patients needs more of some well-defined cures,
02:46some innovative technologies, even in the pharmacological field,
02:50in such a way that the health level of these patients improves,
02:55but at the same time costs are reduced.